This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Investors asking Intra-Cellular for a copy of the scientific poster needed to conduct proper due diligence on ITI-007 are told they can't have it.
7/31/15 9:36AM
The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.
7/30/15 11:03AM
MannKind isn't at risk of shutting down imminently because of the death-spiral convert, but the company was forced into a weakened negotiating position because Afrezza is selling poorly.
7/29/15 10:33AM
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
7/28/15 4:15PM
It's a day that ends in "day," which means cancer immunotherapy is dominating the biotech news.
7/28/15 10:23AM
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
7/27/15 12:42PM
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
7/27/15 10:30AM
After 34 years in existence, Xoma still can't develop a drug successfully on its own.
7/22/15 10:41AM
Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.
7/22/15 7:00AM
Biotech investors, circle November 23 and 24 on your calendars. Use a thick black marker. This will be an epic event for biotech investors.
7/20/15 2:10PM
Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.
7/20/15 7:01AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
7/17/15 6:45AM
Receptos' ozanimod is one of the most compelling late-stage assets in biotech, which makes Celgene's decision to buy it look smart.
7/15/15 9:45AM
The total number of prescriptions written for Gilead Sciences hepatitis C drugs Sovaldi and Harvoni in the U.S. peaked in March and are now in a consistent downtrend.
7/13/15 12:01PM
Anacor intends to seek U.S. approval for a skin rash lotion, crisaborole, in the first half of next year, based on data collected from studies.
7/13/15 7:35AM
The loans negotiated by CEO Linda Powers to a private firm she controls doesn't appear to violate securities laws, but she may have breached fiduciary duty to Northwest Bio shareholders.
7/9/15 12:26PM
On Saturday, July 18, Biogen will present updated results from a closely watched clinical trial involving its Alzheimer's drug candidate aducanumab (formerly known as BIIB037).
7/9/15 10:31AM
Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.
7/7/15 7:43AM
Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.
7/7/15 7:29AM
The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.
7/2/15 2:36PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
7/2/15 12:54PM
The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.
6/30/15 11:27AM
Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.
6/29/15 5:10PM
Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.
6/29/15 11:06AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%
Top Rated Stocks Top Rated Funds Top Rated ETFs